PeptideGlobal

Type 1 diabetes guidelines from WHO back human insulin as countries chase 2030 access goals

WHO's first type 1 diabetes guidelines for adults call for several daily insulin injections adjusted to blood sugar, accept human insulin as effective and set monitoring down to urine tests where nothing else exists.

Illustration for the story: Type 1 diabetes guidelines from WHO back human insulin as countries chase 2030 access goals

Illustration by Peptide Global, not a picture of the place in the story.

The short of itWHO issued its first guidelines on type 1 diabetes in adults, recommending several daily insulin injections adjusted to blood glucose, with human insulin named as an appropriate and effective option.

The World Health Organization has published its first type 1 diabetes guidelines for adults, and they lean on one of the oldest peptide medicines in daily use. Released for World Diabetes Day on 14 November, the guidance tells health systems to give adults with type 1 diabetes several insulin injections a day, adjusted to blood sugar, and names human insulin as an appropriate and effective choice. It is written to work in poor clinics, emergencies and humanitarian crises as well as in hospitals. The question for most countries is less what to prescribe than how to pay for it.

What the WHO recommends

The core advice in the WHO announcement is intensified insulin treatment. Adults should inject insulin several times each day, with each amount matched to measured blood glucose rather than a fixed routine. WHO describes human insulin as an appropriate and effective option and allows other types of insulin when they are clinically needed. For monitoring, the agency recommends a regular clinic blood test that reflects average sugar levels over recent months, plus home checks by finger prick or by a continuous glucose monitor worn on the skin. Where blood glucose testing is not available at all, testing urine for glucose may be considered. The publication itself is titled guidelines on insulin use for type 1 diabetes in adults, including in emergency and humanitarian settings.

WHO also asked countries to involve people who live with type 1 diabetes in designing, running and judging national diabetes programmes, and said it will supply practical tools so that countries can turn the advice into action and track progress. The guidance is meant to apply everywhere, including places where health services have broken down. Dr Søren Brostrøm, WHO director of noncommunicable diseases and mental health, said "insulin is a lifesaving treatment, discovered more than 100 years ago." He added that the guidelines "provide evidence-based recommendations to help countries deliver the best possible care, including in settings where resources are limited and health services are disrupted." The release did not set a single blood sugar target in its public summary.

The access gap behind the type 1 diabetes guidelines

WHO puts the number of people living with type 1 diabetes at about 9.5 million in 2025, with roughly 500,000 new diagnoses that year. Its release says that, more than a century after the discovery of insulin, many of them still cannot get affordable, good quality insulin. Diabetes as a whole is far larger. WHO counts 830 million people with diabetes in 2022, most with type 2, and says more than 40 percent of them do not know they have it. The burden has more than quadrupled since 1990. For type 1 patients, missing insulin is not a matter of poorer control over years; without it, people with the condition do not survive.

An earlier WHO report on access found that just three multinational firms hold more than 90 percent of the world insulin market.

The market structure explains much of the gap. An earlier WHO report on access found that just three multinational firms hold more than 90 percent of the world insulin market. That 2021 report listed high prices, low availability of human insulin and a small number of producers as the main barriers. It also found that human insulin is, in general, as effective as the newer analogues, and that analogues cost at least one and a half times as much. By naming human insulin as appropriate, the new type 1 diabetes guidelines give ministries and insurers cover to buy the cheaper product in bulk, while still allowing analogues where doctors judge them necessary.

ItemDetail
Issued byWorld Health Organization
Date14 November 2026, World Diabetes Day
ScopeAdults with type 1 diabetes, all settings including emergencies
Insulin adviceSeveral daily injections adjusted to blood glucose
Insulin typeHuman insulin appropriate and effective, others when needed
MonitoringPeriodic clinic test, finger prick or continuous monitor at home
FallbackUrine glucose testing where blood testing is unavailable
People with type 1 diabetes, 2025About 9.5 million
New diagnoses, 2025About 500,000
WHO 2030 targetAffordable insulin and self monitoring for all with type 1 diabetes

What it means for insulin makers and buyers

For countries, the guidelines mainly reinforce a buying choice. Health systems that already rely on human insulin from local or regional plants can point to WHO's backing, and those weighing a switch to analogues will need a clinical reason. The advice on monitoring may prove harder to fund. Finger prick strips and continuous glucose monitors are recurring costs on top of the insulin itself, and the guidance asks for both to be within reach. WHO's mention of urine testing as a last resort shows how wide the gap is between rich and poor settings. Our across borders desk follows how such global rules land in individual markets, from tenders to local production.

Several countries are building their own insulin supply, which the guidance may help. Peptide Global has reported on plants such as a new insulin factory in Sri Lanka and Sanofi's insulin site in Frankfurt; these stories sit in our story archive by country and date. Local output can lower prices and protect supply, but only if regulators approve the products and buyers commit to them. The guidelines do not name companies, give prices or set purchasing rules, so their effect depends on what national programmes do next. WHO's own target is that everyone with type 1 diabetes should have access to affordable insulin and blood glucose self monitoring by 2030.

What to watch next

The first thing to watch is how quickly ministries fold the advice into national protocols and essential medicine lists, especially in low income countries and the emergency settings the guidance explicitly covers. The second is the practical tools WHO has promised for tracking progress, which will show how the agency plans to measure access country by country. The third is price. Any new tender rounds for human insulin, or deals by the three dominant makers to supply low income countries, would test whether the guidance moves the market. Data on how many adults still go without insulin will be the clearest measure, and WHO has not yet published a new count.

There are limits to what the public release says. It does not set a numeric blood sugar target, does not spell out how to diagnose type 1 diabetes in adults, and does not rank insulin types by cost or brand. Those details, if present, sit in the full guideline document rather than the announcement. Nor does it say how fast countries are expected to adopt the advice. For now the type 1 diabetes guidelines are a statement of the basic standard: insulin several times a day, a way to measure blood sugar, and patients involved in running the programmes that serve them.

Conclusion

WHO's first type 1 diabetes guidelines for adults back several daily insulin injections, accept human insulin as an effective choice and set out monitoring that runs from glucose sensors down to urine tests. With about 9.5 million people living with the condition and insulin still unaffordable for many, the test is whether countries buy and fund accordingly before 2030.

Why it matters in these markets

About 9.5 million people live with type 1 diabetes and many cannot get affordable insulin. Backing human insulin, which WHO has found as effective as costlier analogues, gives health systems cover to buy the cheaper product.

What to watch

How fast countries add the advice to national protocols and medicine lists, the tracking tools WHO has promised, and insulin tenders or supply deals aimed at the 2030 access target.

Sources

  1. WHO: WHO issues first guidelines on type 1 diabetes for adults
  2. WHO: New WHO report maps barriers to insulin availability and suggests actions to promote universal access
  3. Medical Dialogues: WHO issues first guidelines on type 1 diabetes for adults

Spotted a wrong figure? Tell the desk; we fix errors under our corrections policy.

Peptide Global reports news about medicines and markets. Nothing here is medical or investment advice.